Literature DB >> 22911166

[Hyponatremia : The water-intolerant patient].

J Hensen1.   

Abstract

Hyponatremia due to intolerance to water is a frequent clinical condition and associated with increased mortality. Besides the well known neurological symptoms, gait disturbances, falls, fractures and osteoporosis have also been described recently in patients with chronic hyponatremia. Acute hyponatremia is a more dramatic situation and needs rapid action when severe neurological symptoms are present. Hypertonic saline is recommended to treat this condition until relief of severe symptoms. The causes of hyponatremia have to be carefully examined. Especially diuretics, antidepressants and endocrine causes, e.g. hypothyroidism, hypocortisolism and hypoaldosteronism should be excluded by examination of the patient history, clinical examination and by laboratory tests. Patients should be classified as being euvolemic, hypovolemic or hypervolemic. Whereas acute hyponatremia with severe symptom should be treated with hypertonic saline, euvolemic hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) with mild and moderate symptoms can now be treated with tolvaptan, a selective V(2)-vasopressin antagonist. Oral tolvaptan has been shown to be an effective and potent aquaretic to treat hyponatremia caused by SIADH as evidenced by a simultaneous increase in serum sodium and a decrease in urine osmolality. The condition of patients with mild or moderate hyponatremia is also improved. Side effects associated with tolvaptan include increased thirst, dry mouth, polyuria and hypernatremia. Rapid increases in serum sodium should be avoided by close monitoring in a hospital setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911166     DOI: 10.1007/s00063-012-0115-0

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  30 in total

1.  Thiazides: do they kill?

Authors:  Peter Gross; Catrin Palm
Journal:  Nephrol Dial Transplant       Date:  2005-08-22       Impact factor: 5.992

2.  Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.

Authors:  Benoit Renneboog; Wim Musch; Xavier Vandemergel; Mario U Manto; Guy Decaux
Journal:  Am J Med       Date:  2006-01       Impact factor: 4.965

Review 3.  Clinical practice. The syndrome of inappropriate antidiuresis.

Authors:  David H Ellison; Tomas Berl
Journal:  N Engl J Med       Date:  2007-05-17       Impact factor: 91.245

4.  Hyponatremia due to hypothyroidism: a pure renal mechanism.

Authors:  P H Schmitz; P H de Meijer; A E Meinders
Journal:  Neth J Med       Date:  2001-03       Impact factor: 1.422

5.  Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes.

Authors:  A I Arieff; F Llach; S G Massry
Journal:  Medicine (Baltimore)       Date:  1976-03       Impact factor: 1.889

6.  Oral tolvaptan is safe and effective in chronic hyponatremia.

Authors:  Tomas Berl; Friederike Quittnat-Pelletier; Joseph G Verbalis; Robert W Schrier; Daniel G Bichet; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

7.  Hyponatremia treatment guidelines 2007: expert panel recommendations.

Authors:  Joseph G Verbalis; Stephen R Goldsmith; Arthur Greenberg; Robert W Schrier; Richard H Sterns
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

8.  Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics.

Authors:  Wiebke Fenske; Stefan Störk; Ann-Cathrin Koschker; Anne Blechschmidt; Daniela Lorenz; Sebastian Wortmann; Bruno Allolio
Journal:  J Clin Endocrinol Metab       Date:  2008-05-13       Impact factor: 5.958

Review 9.  Hypopituitarism.

Authors:  Harald Jörn Schneider; Gianluca Aimaretti; Ilonka Kreitschmann-Andermahr; Günter-Karl Stalla; Ezio Ghigo
Journal:  Lancet       Date:  2007-04-28       Impact factor: 79.321

10.  Treatment of euvolemic hyponatremia in the intensive care unit by urea.

Authors:  Guy Decaux; Caroline Andres; Fabrice Gankam Kengne; Alain Soupart
Journal:  Crit Care       Date:  2010-10-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.